ITGA2B and myeloid sarcoma: As the effect of aspirin on general disease activity is inconclusive (205), further studies are needed to determine the benefits and risks of aspirin but also GPIIb/IIIa, GPIb and P2Y12 receptor antagonists in patients with MS.